The successful utilization of TNF inhibitors has paved the path for the advancement of innovative biologic therapies that aim at other crucial cytokines and immune cells that are involved in the pathogenesis of RA (inhibitors of IL-6, such as tocilizumab and sarilumab) and have demonstrated their effectiveness as both standalone treatments and when used in conjunction with methotrexate. The gene discussed is IL6; the disease is rheumatoid arthritis.